The interest of SPF10 PCR-based methods for HPV DNA detection in FFPE samples

Mar 6, 2023

HPV and associated cancers: a global burden

The past decades, prevalence studies have been done using FFPE (Formalin-fixed-paraffin-embedded) tissue specimens to investigate HPV association with a variety of clinical conditions e.g. cervical, anogenital and head and neck cancers, or oral cavity, laryngeal carcinoma, or anal, penile, and vulvar squamous cell carcinoma. The link between cervical cancer and HPV is well-established. Since 2017, direct HPV testing is recommended in the revised WHO/IARC classification to assess a correct diagnosis of the Head and Neck Squamous Cell Carcinoma (HNSCC).1
 

FFPE tissue: an important sample resource

FFPE tissues represent the most frequent form of tissue storage in pathology departments. These archival tissues are a potentially useful resource for epidemiological studies. Several studies have used FFPE specimens to investigate the correlation between HPV genotypes and histological classification, and/or to determine the prevalence of HPV in primary cancers.2-7
 

Fragmentation of DNA in FFPE samples

HPV detection and genotyping in FFPE samples is technically challenging due to poor DNA quality. Formalin fixation can cause DNA damage, including cross-linking and fragmentation.8
 

SPF10 PCR-based methods: most effective and most suitable

HPV DNA PCR methods amplifying shorter fragments of viral genome showed to be more sensitive and amenable for FFPE tissue. SPF10 PCR-based methods are mentioned as the most effective and most suitable for HPV DNA detection in FFPE samples because using a short HPV target region limits the risk of false-negative or invalid results.3,8-11,19
 

The article continues below.

Subscribe to Fujirebio insight updates

Get all the latest insight articles from Fujirebio the moment they are published.

The provision of your data implies your consent to the processing of your data in our database and, depending on the option you choose, to receiving our monthly newsletter by e-mail.

For more information on how we process your personal data and regarding the rights you have in this respect, we refer to our privacy policy, which we hold at your disposal HERE.

If you no longer wish to receive our newsletter, you have the option to unsubscribe via the ‘unsubscribe’ tool at the bottom of the newsletter. If you want to have your data removed from our database, please contact us at: privacy@fujirebio.com.

INNO-LiPA HPV Genotyping Extra II on Formalin-Fixed-Paraffin-Embedded tissue

High sensitivity and specificity:

  • Proven performance on cervical samples12
  • The SPF10 PCR enables identification of HPV infections with low viral load and multiple HPV genotypes in one sample and one testrun12,13,14
  • The small size SPF10 amplicon allows reliable amplification and accurate detection of HPV DNA also from FFPE samples5,6,14,20,21 and first-void urine15,16,17,18
  • Compared to other HPV genotyping methods, INNO-LiPA is more likely to identify HPV genotypes in samples indicating low viral load and FFPE material containing multiple HPV genotypes11

Integrated controls for sample quality:

  • Build-in human DNA control
  • HPV control lines to confirm and detect the presence of a broad range of mucosal HPV genotypes

Prevention of co-amplification or amplicon carry-over:

  • Build-in N-uracil glycosylase-based prevention minimizing the risk of PCR contamination and significantly reducing the possibility of false-positive HPV DNA results3

INNO-LiPA HPV GENOTYPING EXTRA II can play an important role in:

  • Investigation of the prevalence of HPV and genotype distribution in different types of cancer 2,4-6,19-21
  • Evaluation of vaccination trials and monitoring the impact of HPV vaccination (pre-and post-vaccination monitoring)15,18,19
  • Epidemiological studies to investigate the prevalence and distribution of HPV types13,14

References:

  1. Westra W. et al. Head and neck pathology, 2017; 11:41-4
  2. Pretet JL. et al. Int J Cancer, 2008; 122:424-427
  3. Kocjan B. et al. Journal of Clinical Virology, 2016; 76:88-97S88-S97
  4. Sinno A. et al. Obstet Gynecol, 2014; 123:817-821
  5. Acuña G. et al. Modern Pathology, 2019; 32:621-626
  6. Fuglsang K. et al. Papillomavirus Res, 2019; 7:15-20
  7. Valmary-Degano S. et al. Human Pathology, 2013; 44:992-1002
  8. Steinau M. et al. J Mol Diagn, 2011; 13:377-381
  9. Tan SE. et al. J Clin Microbiol, 2010 ; 48 :1458-1460
  10. Querec T. et al. IPVC 2020 Book of Abstracts p.1013-1014
  11. Bicskei B. et al. 2020. J Cancer Sci Clin Ther, 2020; 4:349-364
  12. Xu L. et al. Int J Mol Sci, 2018; 19:2704
  13. Sohrabi A. et al. J Infect Public Health, 2017; 10:730-733
  14. Ahmadi S. et al. Asian Pac J Cancer Prev, 2017;18:3373-3377
  15. O’Leary MC. et al. Br J Cancer, 2011; 104:1221-1226
  16. Ducancelle A. et al. Arch Gynecol Obstet, 2014; 290:299-308
  17. Jannes G. et al. EUROGIN 2018 Poster P10-5
  18. Burroni E. et al. J Med Virol, 2015; 87:508-515
  19. Hillman R. et al. Int J Cancer, 2014; 135 :996-1001
  20. Dalla Libera LS. et al. J Oncol, 2019; Article ID 6018269
  21. Swangvaree SS. et al. Asian Pac J Cancer Prev, 2013; 14:1023-1026

Related articles

Related products

Self-screen HPV-Risk assay

HPV-Risk assay

CE marked
81353
View product
Self-screen Precursor-M+

PreCursor-M+

CE marked
81352
View product

Veuillez confirmer que vous êtes un professionnel de la santé

Le contenu de ce site web est en partie réservé aux professionnels de santé qui sont directement impliqués dans la fourniture de services de soins de santé aux patients. Si vous êtes un professionnel de santé et que vous disposez de tous les droits d'accès, veuillez confirmer en cliquant sur le bouton 'oui'.